Ceci C, Lacal PM, Graziani G. Antibody-drug conjugates: resurgent anticancer agents with multi-targeted therapeutic potential. Pharmacol Ther. 2022;236:108106.

Article  CAS  PubMed  Google Scholar 

Jin Y, Schladetsch MA, Huang X, Balunas MJ, Wiemer AJ. Stepping forward in antibody-drug conjugate development. Pharmacol Ther. 2022;229:107917.

Article  CAS  PubMed  Google Scholar 

Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther. 2022;7:93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boni V, Sharma MR, Patnaik A. The resurgence of antibody drug conjugates in cancer therapeutics: novel targets and payloads. Am Soc Clin Oncol Educ Book. 2020;40:1–17.

PubMed  Google Scholar 

Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev. 2013;32:643–71.

Article  CAS  PubMed  Google Scholar 

Hammarström S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999;9:67–81.

Article  PubMed  Google Scholar 

Decary S, Berne P-F, Nicolazzi C, Lefebvre AM, Dabdoubi T, Cameron B, et al. Preclinical activity of SAR408701: a novel anti-CEACAM5–maytansinoid antibody–drug conjugate for the treatment of CEACAM5-positive epithelial tumors. Clin Cancer Res. 2020;26:6589–99.

Article  CAS  PubMed  Google Scholar 

DeLucia DC, Cardillo TM, Ang L, Labrecque MP, Zhang A, Hopkins JE, et al. Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5–SN38 antibody–drug conjugate in neuroendocrine prostate cancer. Clin Cancer Res 2021;27:759–74.

Article  CAS  PubMed  Google Scholar 

Govindan SV, Cardillo TM, Moon S-J, Hansen HJ, Goldenberg DM. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res 2009;15:6052–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharkey RM, Govindan SV, Cardillo TM, Donnell J, Xia J, Rossi EA, et al. Selective and concentrated accretion of SN-38 with a CEACAM5-targeting antibody–drug conjugate (ADC), labetuzumab govitecan (IMMU-130). Mol Cancer Ther. 2018;17:196–203.

Article  CAS  PubMed  Google Scholar 

Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, et al. A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors. Clin Cancer Res. 2016;22:3286–97.

Article  CAS  PubMed  Google Scholar 

Han ZW, lyv ZW, Cui B, Wang Y. The old CEACAMs find their new role in tumor immunotherapy. Invest New Drugs. 2020;38:1888–98.

Article  PubMed  Google Scholar 

Baek D-S. A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo. Cancer Lett. 2022;525:97–107.

Article  CAS  PubMed  Google Scholar 

Kim YJ, Li W, Zhelev DV, Mellors JW, Dimitrov DS, Baek D-S. Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates. Front Oncol. 2023;13:1124039.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gazzah A. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022;33:416–25.

Article  CAS  PubMed  Google Scholar 

Verhaar ER, Woodham AW, Ploegh HL. Nanobodies in cancer. Semin Immunol. 2021;52:101425.

Article  CAS  PubMed  Google Scholar 

Wu Y, Jiang S, Ying T. Single-domain antibodies as therapeutics against human viral diseases. Front Immunol. 2017;8:1802.

Article  PubMed  PubMed Central  Google Scholar 

Bao C, Gao Q, Li LL, Han L, Zhang B, Ding Y, et al. The application of nanobody in CAR-T therapy. Biomolecules. 2021;11:238.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu Y, Li Q, Kong Y, Wang Z, Lei C, Li J, et al. A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors. Mol Ther. 2022;30:2785–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu Y, Li C, Xia S, Tian X, Kong Y, Wang Z, et al. Identification of human single-domain antibodies against SARS-CoV-2. Cell Host Microbe. 2020;27:891–8.e5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li C, Zhan W, Yang Z, Tu C, Hu G, Zhang X, et al. Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody. Cell. 2022;185:1389–401.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pleiner T, Bates M, Trakhanov S, Lee C-T, Schliep JE, Chug H, et al. Nanobodies: site-specific labeling for super-resolution imaging, rapid epitope-mapping and native protein complex isolation. eLife. 2015;4:e11349.

Article  PubMed  PubMed Central  Google Scholar 

Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Whalen KA, White BH, Quinn JM, Kriksciukaite K, Alargova R, Au Yeung TP, et al. Targeting the somatostatin receptor 2 with the miniaturized drug conjugate, PEN-221: a potent and novel therapeutic for the treatment of small cell lung cancer. Mol Cancer Ther. 2019;18:1926–36.

Article  CAS  PubMed  Google Scholar 

Jung S, Jiang L, Zhao J, Shultz LD, Greiner DL, Bae M, et al. Clathrin light chain-conjugated drug delivery for cancer. Bioeng Transl Med. 2022;8:e10273.

Article  PubMed  PubMed Central  Google Scholar 

Nessler I, Khera E, Vance S, Kopp A, Qiu Q, Keating TA, et al. Increased tumor penetration of single-domain antibody–drug conjugates improves in vivo efficacy in prostate cancer models. Cancer Res. 2020;80:1268–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ewert S, Huber T, Honegger A, Plückthun A. Biophysical properties of human antibody variable domains. J Mol Biol. 2003;325:531–53.

Article  CAS  PubMed  Google Scholar 

Rossotti MA, Bélanger K, Henry KA, Tanha J. Immunogenicity and humanization of single-domain antibodies. FEBS J. 2022;289:4304–27.

Article  CAS  PubMed  Google Scholar 

Xenaki KT, Dorresteijn B, Muns JA, Adamzek K, Doulkeridou S, Houthoff H, et al. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice. Theranostics. 2021;11:5525–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huo J, Le Bas A, Ruza RR, Duyvesteyn HME, Mikolajek H, Malinauskas T, et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol. 2020;27:846–54.

Article  CAS  PubMed  Google Scholar